Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 6/20 | 0.48 |
| ▸ | MAPT | P10636 | 6/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | PPARG | P37231 | 2/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.43 |
| ▸ | PPARA | Q07869 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | NPY1R | P25929 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15063360 | 0.90 | PPARG (0.51) | TP53MAPTSMN1; SMN2POLBPPARG | |
| SCHEMBL15082841 | 0.90 | MAPT (0.55) | TP53MAPTSMN1; SMN2POLBPPARG | |
| SCHEMBL15082869 | 0.90 | MAPT (0.55) | TP53MAPTSMN1; SMN2POLBPPARG | |
| SCHEMBL15063399 | 0.89 | RAB9A (0.49) | TP53MAPTSMN1; SMN2POLBPPARG | |
| SCHEMBL15063498 | 0.88 | PPARG (0.53) | TP53MAPTSMN1; SMN2POLBPPARG | |
| SCHEMBL15082840 | 0.84 | MAPT (0.56) | TP53MAPTSMN1; SMN2POLBPPARG | |
| SCHEMBL15082843 | 0.84 | MAPT (0.60) | TP53MAPTSMN1; SMN2POLBPPARG | |
| SCHEMBL15063496 | 0.84 | PPARG (0.51) | TP53MAPTSMN1; SMN2POLBPPARG | |
| SCHEMBL15063676 | 0.83 | TP53 (0.66) | TP53MAPTSMN1; SMN2POLBFFAR1 | |
| SCHEMBL15063497 | 0.81 | PPARG (0.48) | TP53MAPTSMN1; SMN2POLBPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9540332-B2 | Benzimidazole derivatives as selective blockers of persistent sodium current | ALLERGAN, INC. (US) | 2017-01-10 | — | — | US | disclosed |
| US-9540332-B2 | Benzimidazole derivatives as selective blockers of persistent sodium current | ALLERGAN, INC. (US) | 2017-01-10 | — | — | US | disclosed |
| US-20160355485-A9 | BENZIMIDAZOLE DERIVATIVES AS SELECTIVE BLOCKERS OF PERSISTENT SODIUM CURRENT | ORGANIC SOLUTIONS, INC. | 2016-12-08 | — | — | US | disclosed |
| US-20160355485-A9 | BENZIMIDAZOLE DERIVATIVES AS SELECTIVE BLOCKERS OF PERSISTENT SODIUM CURRENT | ORGANIC SOLUTIONS, INC. | 2016-12-08 | — | — | US | disclosed |
| US-20150011591-A1 | BENZIMIDAZOLE DERIVATIVES AS SELECTIVE BLOCKERS OF PERSISTENT SODIUM CURRENT | ALLERGAN INC (US) | 2015-01-08 | — | — | US | disclosed |
| US-20150011591-A1 | BENZIMIDAZOLE DERIVATIVES AS SELECTIVE BLOCKERS OF PERSISTENT SODIUM CURRENT | ALLERGAN INC (US) | 2015-01-08 | — | — | US | disclosed |
| US-8859780-B2 | Benzimidazole derivatives as selective blockers of persistent sodium current | ALLERGAN, INC. (US) | 2014-10-14 | — | — | US | disclosed |
| US-8859780-B2 | Benzimidazole derivatives as selective blockers of persistent sodium current | ALLERGAN, INC. (US) | 2014-10-14 | — | — | US | disclosed |
| US-20130172389-A1 | BENZIMIDAZOLE DERIVATIVES AS SELECTIVE BLOCKERS OF PERSISTENT SODIUM CURRENT | ALLEGAN, INC. (US) | 2013-07-04 | — | — | US | disclosed |
| US-20130172389-A1 | BENZIMIDAZOLE DERIVATIVES AS SELECTIVE BLOCKERS OF PERSISTENT SODIUM CURRENT | ALLEGAN, INC. (US) | 2013-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150011591-A1 | BENZIMIDAZOLE DERIVATIVES AS SELECTIVE BLOCKERS OF PERSISTENT SODIUM CURRENT | SCN1B, CACNA1E, SCN2B | TP53 4414/4885MAPT 2318/4885SMN1; SMN2 353/4885 |
| US-20130172389-A1 | BENZIMIDAZOLE DERIVATIVES AS SELECTIVE BLOCKERS OF PERSISTENT SODIUM CURRENT | SCN1B, CACNA1E, SCN2B | TP53 4414/4885MAPT 2318/4885SMN1; SMN2 353/4885 |
| US-20160355485-A9 | BENZIMIDAZOLE DERIVATIVES AS SELECTIVE BLOCKERS OF PERSISTENT SODIUM CURRENT | SCN1B, CACNA1E, SCN2B | TP53 4414/4885MAPT 2318/4885SMN1; SMN2 353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.